Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Comment: Osimertinib for EGFR-mutation positive NSCLC

Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain

Comment: Osimertinib for EGFR-mutation positive NSCLC ( Dr Pilar Garrido - University Hospital Ramón y Cajal, Madrid, Spain )

Nivolumab plus ipilimumab combination offers chemotherapy-free option for...

Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne...

Nivolumab plus ipilimumab combination offers chemotherapy-free option for advanced NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )

Front-line osimertinib significantly lengthens overall survival in EGFR...

Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta...

Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Prof Suresh Ramalingam - Winship Cancer Institute of Emory University, Atlanta, USA )

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer

Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK

Comment: PARP inhibitor olaparib plus bevacizumab in women with ovarian cancer ( Dr Susana Banerjee - The Royal Marsden NHS Foundation Trust, London, UK )

More ovarian cancer patients benefit from maintenance combined targeted therapy

Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France

More ovarian cancer patients benefit from maintenance combined targeted therapy ( Prof Isabelle Ray-Coquard - The Université Claude Bernard Lyon, Lyon, France )

Comment: Immunotherapy combination for advanced NSCLC

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Immunotherapy combination for advanced NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Comment: Front-line osimertinib significantly lengthens overall survival in...

Dr Marina Garassino - National Tumour Institute, Milan, Italy

Comment: Front-line osimertinib significantly lengthens overall survival in EGFR-mutation positive NSCLC ( Dr Marina Garassino - National Tumour Institute, Milan, Italy )

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre...

Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium

Real-world use of carfilzomib in relapsed multiple myeloma patients with pre-existing cardiovascular comorbidities ( Dr Jo Caers - Centre Hospitalier Universitaire de Liège, Liège, Belgium )

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk...

Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands

D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands )

Adding daratumumab to existing multiple myeloma regimen of lenalidomide...

Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA

Adding daratumumab to existing multiple myeloma regimen of lenalidomide, bortezomib and dexamethasone ( Prof Peter Voorhees - Levine Cancer Institute, Charlotte, USA )

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

A phase 1b study of once-weekly KRd in patients with newly diagnosed multiple myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr...

Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA

Synthesis, preclinical analysis, and first-inhuman phase I imaging of 89Zr-DFOdaratumumab for CD38 targeted imaging of myeloma ( Prof Ola Landgren - Memorial Sloan Kettering Cancer Center, New York City, USA )

More from ecancer